BEAM
Income statement / Annual
Last year (2024), Beam Therapeutics Inc.'s total revenue was $63.52 M,
a decrease of 83.18% from the previous year.
In 2024, Beam Therapeutics Inc.'s net income was -$376.74 M.
See Beam Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$63.52 M |
$377.71 M |
$60.92 M |
$51.84 M |
$24.00 K |
$18.00 K |
$0.00 |
$0.00 |
| Cost of Revenue |
$367.56 M
|
$0.00
|
$311.59 M
|
$232.13 M
|
$103.18 M
|
$54.62 M
|
$33.87 M
|
$0.00
|
| Gross Profit |
-$304.04 M
|
$377.71 M
|
-$250.67 M
|
-$180.29 M
|
-$103.16 M
|
-$54.60 M
|
-$33.87 M
|
$0.00
|
| Gross Profit Ratio |
-4.79
|
1
|
-4.11
|
-3.48
|
-4298.13
|
-3033.39
|
0
|
0
|
| Research and Development Expenses |
$367.56 M
|
$437.38 M
|
$311.59 M
|
$387.09 M
|
$103.18 M
|
$54.62 M
|
$33.87 M
|
$5.86 M
|
| General & Administrative Expenses |
$111.53 M
|
$116.81 M
|
$87.81 M
|
$57.22 M
|
$29.61 M
|
$20.55 M
|
$11.87 M
|
$2.02 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$111.53 M
|
$116.81 M
|
$87.81 M
|
$57.22 M
|
$29.61 M
|
$20.55 M
|
$11.87 M
|
$2.20 M
|
| Other Expenses |
-$367.56 M
|
$0.00
|
-$311.59 M
|
-$232.13 M
|
-$103.18 M
|
-$54.62 M
|
-$33.87 M
|
$0.00
|
| Operating Expenses |
$111.53 M
|
$554.19 M
|
$87.81 M
|
$212.18 M
|
$29.60 M
|
$20.55 M
|
$11.87 M
|
$8.60 M
|
| Cost And Expenses |
$479.09 M
|
$554.19 M
|
$399.40 M
|
$444.31 M
|
$132.78 M
|
$75.17 M
|
$45.74 M
|
$7.88 M
|
| Interest Income |
$49.09 M
|
$0.00
|
$0.00
|
$0.00
|
$1.57 M
|
$2.49 M
|
$292.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$187.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$21.93 M
|
$29.53 M
|
$14.15 M
|
$7.45 M
|
$4.73 M
|
$3.50 M
|
$650.00 K
|
$12.00 K
|
| EBITDA |
-$393.64 M |
-$146.95 M |
-$324.33 M |
-$230.06 M |
-$128.03 M |
-$71.65 M |
-$45.09 M |
-$8.58 M |
| EBITDA Ratio |
-6.2
|
-0.39
|
-5.32
|
-4.44
|
-5334.38
|
-3980.61
|
0
|
0
|
| Operating Income Ratio |
-6.54
|
-0.47
|
-5.56
|
-7.57
|
-5531.67
|
-4175.22
|
0
|
0
|
| Total Other Income/Expenses Net |
$38.87 M
|
$45.32 M
|
$52.80 M
|
$21.83 M
|
-$61.83 M
|
-$3.17 M
|
-$71.00 M
|
-$133.09 K
|
| Income Before Tax |
-$376.70 M
|
-$131.16 M
|
-$285.68 M
|
-$370.64 M
|
-$194.59 M
|
-$78.33 M
|
-$116.74 M
|
-$8.73 M
|
| Income Before Tax Ratio |
-5.93
|
-0.35
|
-4.69
|
-7.15
|
-8108
|
-4351.44
|
0
|
0
|
| Income Tax Expense |
$39.00 K
|
$1.37 M
|
$3.41 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$500.00 K
|
| Net Income |
-$376.74 M
|
-$132.53 M
|
-$289.09 M
|
-$370.64 M
|
-$194.59 M
|
-$78.33 M
|
-$115.26 M
|
-$8.73 M
|
| Net Income Ratio |
-5.93
|
-0.35
|
-4.75
|
-7.15
|
-8108
|
-4351.44
|
0
|
0
|
| EPS |
-4.58 |
-1.72 |
-4.13 |
-5.77 |
-5.49 |
-1.53 |
-3.28 |
-0.62 |
| EPS Diluted |
-4.58 |
-1.72 |
-4.13 |
-5.77 |
-5.49 |
-1.53 |
-3.28 |
-0.62 |
| Weighted Average Shares Out |
$82.31 M
|
$77.15 M
|
$70.02 M
|
$64.23 M
|
$46.73 M
|
$51.34 M
|
$35.14 M
|
$12.95 M
|
| Weighted Average Shares Out Diluted |
$82.31 M
|
$77.15 M
|
$70.02 M
|
$64.23 M
|
$46.73 M
|
$51.34 M
|
$35.14 M
|
$12.95 M
|
| Link |
|
|
|
|
|
|
|
|
